drugset
drugset / Trial / NCT00831896

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

NCT00831896 ↗

Phase 1 Completed 27 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans. The primary purpose of this study is to determine the safety profile, tolerability, and pharmacokinetics profile of TAK-701.

Timeline

Start
2009-03
Primary completion
2010-11
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK 701 Unknown 2 mg/kg Intravenous
Subject TAK 701 Unknown 5 mg/kg Intravenous
Subject TAK 701 Unknown 10 mg/kg Intravenous
Subject TAK 701 Unknown 20 mg/kg Intravenous

Indications

cancer